BCG 010
Alternative Names: BCG-010Latest Information Update: 16 Jul 2026
At a glance
- Originator Beijing Biocytogen
- Developer Beijing Biocytogen; Undisclosed
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action NK cell lectin-like receptor subfamily C antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Apr 2026 Preclinical trials in Cancer in China (Parenteral)
- 17 Apr 2026 Pharmacodynamics and pharamcokinetics data from a preclinical trial in Cancer presented at the 117th Annual Meeting of the American Association for Cancer Research 2026 (AACR-2026)
- 14 Jun 2023 Pharmacodynamics data from preclinical trial in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)